Vagus nerve stimulation for migraine isn’t speculative — it’s FDA-cleared, clinically tested, and commercially available. The gammaCore device, manufactured by electroCore, delivers non-invasive cervical vagus nerve stimulation (nVNS) and holds clearances for both acute treatment and prevention of migraine and cluster headache. But understanding what it actually does, how well it works, and who it’s appropriate for requires looking past the marketing into the clinical data and neuroscience.
Why the Vagus Nerve Matters in Migraine
Migraine is fundamentally a neurovascular disorder involving abnormal activation of the trigeminovascular system. The trigeminal nerve — which innervates the meninges and intracranial blood vessels — releases calcitonin gene-related peptide (CGRP) during a migraine attack, causing neurogenic inflammation, vasodilation, and the characteristic throbbing pain.
The vagus nerve connection comes through brainstem anatomy. The trigeminal nucleus caudalis (TNC) — the brainstem relay for head and face pain — shares extensive connections with the nucleus tractus solitarius (NTS), the primary vagal sensory nucleus. Stimulating the vagus nerve activates the NTS, which modulates activity in the TNC, potentially dampening the trigeminal pain processing that drives migraine.
Additionally, vagal stimulation activates descending pain inhibitory pathways from the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), releasing serotonin and noradrenaline that suppress nociceptive transmission in the spinal trigeminal nucleus. Some evidence suggests VNS also reduces CGRP levels, though this mechanism is less well established in humans than in animal models.
gammaCore: How It Works
The gammaCore device is a handheld stimulator placed against the side of the neck over the vagus nerve. It delivers a proprietary electrical signal — a low-voltage burst of five sine waves at 5 kHz, repeated 25 times per second — through the skin to stimulate the cervical vagus nerve. Each treatment dose consists of two consecutive two-minute stimulations on one side of the neck.
This is cervical non-invasive VNS (nVNS) — fundamentally different from implanted VNS (which requires surgery to wrap an electrode around the vagus nerve) and from transcutaneous auricular VNS (taVNS, which stimulates the auricular branch at the ear). Cervical nVNS targets the main vagal trunk, delivering stimulation to both afferent and efferent fibres. The stimulation parameters are designed to activate A-beta and A-delta vagal fibres while minimising activation of unmyelinated C-fibres.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Clinical Trial Evidence
The evidence base for gammaCore in migraine comes from several key trials, though results are more modest than some marketing materials suggest.
The PREMIUM trial (Prevention of Migraine via Induction of the Unilateral Migraine through nVNS) was a randomised, double-blind, sham-controlled study of 477 episodic migraine patients using nVNS preventively. The primary endpoint — reduction in migraine days at month three — narrowly missed statistical significance. However, the open-label extension and subset analyses showed approximately a two-day per month reduction in migraine frequency, and the device was well tolerated with no serious adverse events.
For acute migraine treatment, the PRESTO trial demonstrated that nVNS was more effective than sham at achieving pain-free status at 30 minutes and 60 minutes post-treatment, with a statistically significant responder rate difference. The effect sizes, while statistically significant, were modest compared to triptans — the standard acute migraine treatment.
The evidence is stronger for cluster headache. The ACT1 trial showed nVNS significantly outperformed sham for acute treatment of episodic cluster headache, with a 34% response rate versus 11% for sham at 15 minutes. For chronic cluster headache, results were less clear, but nVNS showed benefit as an adjunctive preventive treatment in the ACT2 trial.
Where nVNS Fits in Migraine Treatment
Understanding gammaCore’s role requires context within the broader migraine treatment landscape.
First-line treatments for most migraine patients remain lifestyle modification (sleep regularity, trigger identification, stress management), acute medications (NSAIDs, triptans, gepants), and preventive medications for those with frequent attacks (beta-blockers, topiramate, amitriptyline, or CGRP-targeted therapies).
CGRP-targeted therapies — monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and gepants (ubrogepant, rimegepant, atogepant) — have transformed migraine prevention since their introduction starting in 2018. These address the CGRP pathway directly and show larger effect sizes than nVNS in most comparative analyses.
gammaCore occupies a specific niche: patients who want a drug-free option, cannot tolerate or have contraindications to standard medications, prefer to avoid daily medication, or want an adjunctive treatment alongside their current regimen. It’s also relevant for pregnant patients, where medication options are limited, and for patients with medication-overuse headache who need to reduce their acute medication use.
The device is not a replacement for triptans in patients who respond well to them. A realistic expectation is modest benefit — a reduction of one to two migraine days per month when used preventively, and a lower probability of acute attack resolution compared to triptans but with essentially no systemic side effects.
Implanted VNS for Refractory Migraine
Implanted VNS — using devices like those manufactured by LivaNova, originally developed for epilepsy — has been studied off-label for chronic migraine, though it lacks formal migraine-specific approval. The rationale is that continuous, programmable vagal stimulation provides more sustained modulation of trigeminovascular pathways than intermittent non-invasive stimulation.
Case series and small trials have reported benefit in some patients with refractory chronic migraine, but the invasiveness of the procedure (surgical implantation under general anaesthesia, battery replacement every several years) limits its application to patients who have exhausted other options. Potential side effects include hoarseness during stimulation, cough, and the surgical risks of any implanted device.
Transcutaneous Auricular VNS for Migraine
Stimulating the auricular branch of the vagus nerve (ABVN) at the cymba conchae or tragus of the ear is a third vagal stimulation approach being studied for migraine. The NEMOS device (Cerbomed) has received CE marking in Europe for migraine prevention. Several small trials have shown reductions in migraine frequency, though the evidence base is smaller than for cervical nVNS.
The auricular approach stimulates vagal afferents that project to the NTS, activating similar brainstem pathways as cervical stimulation. Typical parameters are 25 Hz frequency with 200-250 microsecond pulse width, applied for 1-4 hours daily. Whether auricular stimulation provides equivalent vagal activation to cervical stimulation is debated — fMRI studies confirm NTS activation with both approaches, but the relative magnitude may differ.
Practical Considerations
gammaCore requires a prescription and currently costs approximately $300-600 per month in the US without insurance. Some insurance plans cover it, particularly after failure of multiple preventive medications. Each device contains a set number of treatment doses and must be replaced when depleted.
Side effects are minimal: mild neck discomfort during stimulation, occasional lip or facial twitching from current spread, and rare lightheadedness. There are no drug interactions and no systemic side effects — a genuine advantage over pharmacological options.
For patients considering nVNS, the practical advice is to use it consistently for at least two to three months before judging efficacy for prevention, as the benefit appears to build over time. For acute use, applying the treatment at the earliest sign of an attack yields better results than waiting for fully established pain.
Want to understand the full picture of how vagus nerve stimulation works — for migraine and beyond? Get My Vagus Nerve & Me eBook for a clear guide to the science, devices, and techniques that genuinely modulate vagal function.
